RevvityRVTY
RVTY
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 192 | Existing positions reduced: 160
20% more call options, than puts
Call options by funds: $1.77M | Put options by funds: $1.48M
10% more first-time investments, than exits
New positions opened: 66 | Existing positions closed: 60
3.61% more ownership
Funds ownership: 87.9% [Q3] → 91.51% (+3.61%) [Q4]
0% less funds holding
Funds holding: 517 [Q3] → 515 (-2) [Q4]
4% less capital invested
Capital invested by funds: $13.8B [Q3] → $13.2B (-$591M) [Q4]
25% less funds holding in top 10
Funds holding in top 10: 8 [Q3] → 6 (-2) [Q4]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$140
34%
upside
Avg. target
$143
38%
upside
High target
$145
39%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Barclays Luke Sergott 22% 1-year accuracy 11 / 51 met price target | 34%upside $140 | Overweight Maintained | 3 Feb 2025 |
Raymond James Andrew Cooper 13% 1-year accuracy 2 / 16 met price target | 39%upside $145 | Outperform Reiterated | 3 Feb 2025 |
Keybanc Paul Knight 22% 1-year accuracy 2 / 9 met price target | 39%upside $145 | Overweight Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 4 articles about RVTY published over the past 30 days
Negative
Investors Business Daily
5 days ago
How Tariffs Are Rocking The 'Bubblegum And Shoestring' Medical Supply Chain
Tariff uncertainty has cast a pall over medical stocks. Re-shoring is possible, but expensive, leaving them in a "wait-and-see" pattern.

Positive
Zacks Investment Research
1 week ago
Revvity Stock Tumbles Despite Expanding Genomics England Alliance
RVTY expands its alliance with Genomics England to boost newborn genomic sequencing research, aiming to enhance early diagnosis and healthcare outcomes.

Neutral
Business Wire
1 week ago
Revvity Expands Alliance with Genomics England to Drive Research into Newborn Genomic Sequencing in England
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity announced an agreement with Genomics England to further collaborate on the Generation Study by providing sequencing services.

Neutral
Business Wire
4 weeks ago
Revvity's EUROIMMUN Receives CE Mark for Novel Measles Antibody Detection Assay
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against measles virus. EUROIMMUN's Anti-Measles Virus ELISA 2.0 (IgG) is the first of several assays in development expanding EUROIMMUN's serological infection diagnostics portfolio with validation for dried blood spots (DBS) as sample material in addition to ser.

Neutral
Business Wire
1 month ago
Revvity Wins Permanent Injunction Enforcing Agreements with Cloud Software Group
WALTHAM, Mass.--(BUSINESS WIRE)--Today, Revvity, Inc. (NYSE: RVTY) announced that the Massachusetts Superior Court has ruled in its favor and will issue a permanent injunction to enforce Revvity's rights under its agreements with Cloud Software Group (CSG) related to the Spotfire® software. This ruling follows a preliminary injunction issued in April 2024, which will become permanent, ensuring uninterrupted access to Spotfire software and support for Revvity and its customers, protecting operat.

Neutral
Business Wire
1 month ago
Revvity to Present at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences in March 2025: 46th Annual Raymond James Institutional Investor Conference Monday, March 3, 2025 7:30 a.m. ET - Max Krakowiak, senior vice president and chief financial officer TD Cowen 45th Annual Health Care Conference Tuesday, March 4, 2025 9:10 a.m. ET - Prahlad Singh, president and chief executive officer Leerink Partners Global Healthcare Conference Tuesday, M.

Positive
Zacks Investment Research
1 month ago
RVTY Q4 Earnings Beat Estimates, Sales Miss, Segments Robust
Revvity's fourth-quarter results showcase strong growth in Diagnostics business, along with recovery in Life Sciences segmental sales.

Neutral
Zacks Investment Research
1 month ago
Revvity (RVTY) Reports Q4 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Neutral
Seeking Alpha
1 month ago
Revvity, Inc. (RVTY) Q4 2024 Earnings Call Transcript
Revvity, Inc. (NYSE:RVTY ) Q4 2024 Earnings Conference Call January 31, 2025 8:00 AM ET Company Participants Steve Willoughby - Senior Vice President, Investor Relations Prahlad Singh - President & Chief Executive Officer Max Krakowiak - Senior Vice President & Chief Financial Officer Conference Call Participants Doug Schenkel - Wolfe Research Vijay Kumar - Evercore ISI Patrick Donnelly - Citi Michael Ryskin - Bank of America Puneet Souda - Leerink Partners Matt Sykes - Goldman Sachs Luke Sergott - Barclays Andrew Cooper - Raymond James Catherine Schulte - Baird Dan Brennan - TD Cowen Operator Hello, everyone, and welcome to Revvity's Fourth Quarter 2024 Earnings Call. My name is Lydia, and I will be your operator today.

Positive
Zacks Investment Research
1 month ago
Revvity (RVTY) Surpasses Q4 Earnings Estimates
Revvity (RVTY) came out with quarterly earnings of $1.42 per share, beating the Zacks Consensus Estimate of $1.36 per share. This compares to earnings of $1.25 per share a year ago.

Charts implemented using Lightweight Charts™